Kenneth Cusi

Kenneth Cusi, MD, FACP, FACE

Chief, Endocrinology; VA Faculty

Department: MD-ENDOCRINOLOGY
Business Phone: (352) 273-8655
Business Email: kcusi@ufl.edu

About Kenneth Cusi

Dr. Kenneth Cusi serves as Chief of the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida. He received his medical degree in Argentina from the University of Buenos Aires School of Medicine and is board certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism.  He completed his residency at the Center of Medical Education & Clinical Research (CEMIC) in Buenos Aires, Argentina, and a clinical fellowship at Baylor College of Medicine in Houston. Prior to joining the University of Florida, Dr. Cusi was a faculty member of over 15 years in the Diabetes Division at the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Veterans Health Administration System in Texas; one of the leading diabetes programs in the country.  He is a fellow of the American College of Physicians (ACP) and the American Association of Clinical Endocrinologists (AACE). He has actively participated in many clinical diabetes programs and in the training of many young researchers and clinicians.  He is the principal investigator of various ongoing clinical translational research projects in obesity, Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).

Board Certifications

  • Endocrinology, Diabetes, and Metabolism
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Medicine
Areas of Interest
  • Diabetes
  • Diabetes – resources
  • Type 2 diabetes

Research Profile

Areas of Interest
  • Metabolic syndrome
  • Non-alcoholic Fatty Liver Disease
  • Type 2 Diabetes

Publications

2021
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Diabetes care. 44(2):399-406 [DOI] 10.2337/dc20-1997. [PMID] 33355256.
2021
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Nature reviews. Gastroenterology & hepatology. 18(1):24-39 [DOI] 10.1038/s41575-020-00366-5. [PMID] 33093663.
2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine. [DOI] 10.1056/NEJMoa2028395. [PMID] 33185364.
2020
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.
Diabetes care. 43(2):275-279 [DOI] 10.2337/dci19-0064. [PMID] 31959644.
2020
Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Metabolism: clinical and experimental. 110 [DOI] 10.1016/j.metabol.2020.154297. [PMID] 32562798.
2020
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
Contemporary clinical trials. 97 [DOI] 10.1016/j.cct.2020.106174. [PMID] 33039693.
2020
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Current diabetes reports. 20(11) [DOI] 10.1007/s11892-020-01349-1. [PMID] 33015726.
2020
Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 68(3):743-747 [DOI] 10.1136/jim-2019-001186. [PMID] 31852748.
2020
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Diabetes care. 43(2):290-297 [DOI] 10.2337/dc19-1071. [PMID] 31604692.
2020
A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.
Liver international : official journal of the International Association for the Study of the Liver. 40 Suppl 1:82-88 [DOI] 10.1111/liv.14350. [PMID] 32077613.
2020
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
Annals of hepatology. 19(6):674-690 [DOI] 10.1016/j.aohep.2020.09.006. [PMID] 33031970.
2020
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Journal of hepatology. 72(4):613-626 [DOI] 10.1016/j.jhep.2019.10.023. [PMID] 31697972.
2020
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Journal of hepatology. 72(3):401-410 [DOI] 10.1016/j.jhep.2019.09.018. [PMID] 31589891.
2020
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.
Current opinion in lipidology. 31(6):364-366 [DOI] 10.1097/MOL.0000000000000717. [PMID] 33149083.
2020
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
The American journal of medicine. 133(5):536-543 [DOI] 10.1016/j.amjmed.2020.01.007. [PMID] 32017891.
2019
Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes.
Diabetes care. 42(7):1348-1351 [DOI] 10.2337/dc18-2578. [PMID] 31221701.
2019
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Diabetes care. 42(8):1481-1488 [DOI] 10.2337/dc19-0167. [PMID] 31332029.
2019
Re: “Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis” by Mantovani et al. (Thyroid 2018;28:1270-1284).
Thyroid : official journal of the American Thyroid Association. 29(3) [DOI] 10.1089/thy.2018.0622. [PMID] 30652529.
2019
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism. 104(8):3327-3336 [DOI] 10.1210/jc.2018-02414. [PMID] 30848827.
2019
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 67(2):303-311 [DOI] 10.1136/jim-2018-000864. [PMID] 30309884.
2019
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
The lancet. Diabetes & endocrinology. 7(4):313-324 [DOI] 10.1016/S2213-8587(18)30154-2. [PMID] 30174213.
2019
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
Hepatology (Baltimore, Md.). 70(2):711-724 [DOI] 10.1002/hep.30429. [PMID] 30556145.
2019
Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities.
Obesity (Silver Spring, Md.). 27(7):1099-1106 [DOI] 10.1002/oby.22508. [PMID] 31116012.
2019
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Hepatology (Baltimore, Md.). 69(6):2318-2322 [DOI] 10.1002/hep.30670. [PMID] 31006135.
2019
Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis.
PloS one. 14(7) [DOI] 10.1371/journal.pone.0219855. [PMID] 31318914.
2019
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Journal of diabetes. 11(3):223-231 [DOI] 10.1111/1753-0407.12833. [PMID] 30073778.
2019
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Diabetes, obesity & metabolism. 21(4):812-821 [DOI] 10.1111/dom.13584. [PMID] 30447037.
2019
Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial.
Experimental gerontology. 116:46-53 [DOI] 10.1016/j.exger.2018.12.013. [PMID] 30576716.
2019
Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content”.
The Journal of clinical endocrinology and metabolism. 104(11):5249-5250 [DOI] 10.1210/jc.2019-00970. [PMID] 31225877.
2019
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
The Journal of endocrinology. 241(3):293-305 [DOI] 10.1530/JOE-19-0007. [PMID] 31082799.
2018
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
American journal of physiology. Endocrinology and metabolism. 315(2):E163-E173 [DOI] 10.1152/ajpendo.00023.2018. [PMID] 29634314.
2018
Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Diabetes, obesity & metabolism. 20(7):1702-1709 [DOI] 10.1111/dom.13285. [PMID] 29527789.
2018
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology (Baltimore, Md.). 67(1):328-357 [DOI] 10.1002/hep.29367. [PMID] 28714183.
2018
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 16(4):558-566.e2 [DOI] 10.1016/j.cgh.2017.12.001. [PMID] 29223443.
2018
Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187-192.
Diabetes care. 41(9):e137-e138 [DOI] 10.2337/dci18-0026. [PMID] 30135202.
2018
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
Gut. 67(7) [DOI] 10.1136/gutjnl-2017-313958. [PMID] 28408383.
2018
Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH.
Alimentary pharmacology & therapeutics. 47(8):1220-1221 [DOI] 10.1111/apt.14473. [PMID] 29574870.
2018
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.
Frontiers in pharmacology. 9 [DOI] 10.3389/fphar.2018.00752. [PMID] 30065651.
2018
Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.
Diabetes care. 41(1):187-192 [DOI] 10.2337/dc17-1349. [PMID] 29133343.
2018
Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 66(1):7-10 [DOI] 10.1136/jim-2017-000554. [PMID] 28918389.
2018
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Diabetic medicine : a journal of the British Diabetic Association. 35(10):1434-1439 [DOI] 10.1111/dme.13697. [PMID] 29869810.
2018
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 66(3):661-668 [DOI] 10.1136/jim-2017-000609. [PMID] 29167192.
2017
The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt’s Syndrome.
Journal of investigative medicine high impact case reports. 5(3) [DOI] 10.1177/2324709617716203. [PMID] 28748191.
2017
Nonalcoholic steatohepatitis in nonobese patients: Not so different after all.
Hepatology (Baltimore, Md.). 65(1):4-7 [DOI] 10.1002/hep.28839. [PMID] 27650699.
2017
Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Diabetes, obesity & metabolism. 19(11):1630-1634 [DOI] 10.1111/dom.12973. [PMID] 28417532.
2017
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Trends in endocrinology and metabolism: TEM. 28(4):250-260 [DOI] 10.1016/j.tem.2016.11.006. [PMID] 27986466.
2017
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 65(4):1132-1144 [DOI] 10.1002/hep.28985. [PMID] 27981615.
2017
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.
Diabetes care. 40(3):419-430 [DOI] 10.2337/dc16-1787. [PMID] 28223446.
2017
Reply to “statins and non-alcoholic steatohepatitis”.
Metabolism: clinical and experimental. 66:e3-e5 [DOI] 10.1016/j.metabol.2016.10.004. [PMID] 27865560.
2017
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
The Journal of clinical endocrinology and metabolism. 102(8):2950-2961 [DOI] 10.1210/jc.2017-00867. [PMID] 28575232.
2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.
Hepatology (Baltimore, Md.). 66(1):296-297 [DOI] 10.1002/hep.29150. [PMID] 28295426.
2017
Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy.
American journal of clinical oncology. 40(4):433-437 [DOI] 10.1097/COC.0000000000000180. [PMID] 25730603.
2017
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Contemporary clinical trials. 61:33-38 [DOI] 10.1016/j.cct.2017.07.015. [PMID] 28735109.
2017
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
Alimentary pharmacology & therapeutics. 46(1):56-61 [DOI] 10.1111/apt.14111. [PMID] 28470881.
2017
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.
Annals of internal medicine. 166(3) [DOI] 10.7326/L16-0629. [PMID] 28166556.
2016
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Diabetologia. 59(6):1112-20 [DOI] 10.1007/s00125-016-3952-1. [PMID] 27101131.
2016
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.
Clinical diabetes and endocrinology. 2 [DOI] 10.1186/s40842-016-0027-7. [PMID] 28702244.
2016
Prediabetes: A Worldwide Epidemic.
Endocrinology and metabolism clinics of North America. 45(4):751-764 [DOI] 10.1016/j.ecl.2016.06.007. [PMID] 27823603.
2016
Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 64(1):63-8 [DOI] 10.1136/jim-2015-000019. [PMID] 26755815.
2016
Pharmacological management of nonalcoholic fatty liver disease.
Metabolism: clinical and experimental. 65(8):1183-95 [DOI] 10.1016/j.metabol.2016.04.004. [PMID] 27301803.
2016
Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
Endocrinology and metabolism clinics of North America. 45(4):765-781 [DOI] 10.1016/j.ecl.2016.06.005. [PMID] 27823604.
2016
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
Diabetes care. 39(4):632-8 [DOI] 10.2337/dc15-1876. [PMID] 26861926.
2016
Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.
American journal of physiology. Endocrinology and metabolism. 310(7):E484-94 [DOI] 10.1152/ajpendo.00492.2015. [PMID] 26814015.
2016
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
The Journal of clinical endocrinology and metabolism. 101(2):644-52 [DOI] 10.1210/jc.2015-3111. [PMID] 26672634.
2016
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Diabetes, obesity & metabolism. 18 Suppl 2:50-58 [DOI] 10.1111/dom.12751. [PMID] 27723227.
2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine. 165(5):305-15 [DOI] 10.7326/M15-1774. [PMID] 27322798.
2016
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Current opinion in lipidology. 27(6):633-635 [PMID] 27805974.
View on: PubMed
2015
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism. 100(6):2231-8 [DOI] 10.1210/jc.2015-1966. [PMID] 25885947.
2015
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.
Liver international : official journal of the International Association for the Study of the Liver. 35(9):2139-46 [DOI] 10.1111/liv.12840. [PMID] 25847730.
2015
Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.
American journal of physiology. Endocrinology and metabolism. 309(4):E311-9 [DOI] 10.1152/ajpendo.00161.2015. [PMID] 26058864.
2015
Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
Journal of hepatology. 62(2):405-11 [DOI] 10.1016/j.jhep.2014.08.040. [PMID] 25195551.
2015
The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 61(1):153-60 [DOI] 10.1002/hep.27395. [PMID] 25145475.
2015
Therapy and clinical trials.
Current opinion in lipidology. 26(5):472-4 [DOI] 10.1097/MOL.0000000000000225. [PMID] 26339771.
2015
Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?
Liver international : official journal of the International Association for the Study of the Liver. 35(10):2341-2 [DOI] 10.1111/liv.12869. [PMID] 25964992.
2014
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 969:219-23 [DOI] 10.1016/j.jchromb.2014.08.019. [PMID] 25195022.
2014
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism. 100(5) [DOI] 10.1210/jc.2014-2739. [PMID] 25303488.
2014
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Journal of hepatology. 60(1):167-74 [DOI] 10.1016/j.jhep.2013.07.042. [PMID] 23973932.
2014
Multivariate Analysis of Factors That Influence Improvement in Nonalcoholic Fatty Liver Disease (Nafld) After Pioglitazone Treatment.
Pharmacotherapy. 34(10)
2014
Pharmacodynamic Association of Pioglitazone and Its Active Metabolites With Liver Outcomes Among Patients Diagnosed With Nonalcoholic Steatohepatitis.
Clinical Pharmacology & Therapeutics. 95(1)
2014
Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 59(6):2178-87 [DOI] 10.1002/hep.26988. [PMID] 24777953.
2014
The relationship between hepatitis C virus infection and diabetes: time for a divorce?
Hepatology (Baltimore, Md.). 60(4):1121-3 [DOI] 10.1002/hep.27252. [PMID] 24913680.
2013
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Drugs. 73(1):1-14 [DOI] 10.1007/s40265-012-0004-0. [PMID] 23329465.
2013
Plasma Branch Chain and Aromatic Amino Acid Levels Are Associated With Insulin Resistance in Nonalcoholic Fatty Liver Disease (Nafld)
The FASEB's Journal. 27
2013
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
Current diabetes reports. 13(3):329-41 [DOI] 10.1007/s11892-013-0378-8. [PMID] 23625197.
2012
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
Gastroenterology. 142(7):1592-609 [DOI] 10.1053/j.gastro.2012.04.001. [PMID] 22656328.
2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology (Baltimore, Md.). 55(6):2005-23 [DOI] 10.1002/hep.25762. [PMID] 22488764.
2012
Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Gastroenterology. 142(4):711-725.e6 [DOI] 10.1053/j.gastro.2012.02.003. [PMID] 22326434.
2012
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
The American journal of gastroenterology. 107(6):811-26 [DOI] 10.1038/ajg.2012.128. [PMID] 22641309.
2012
Metabolic and Histological Effects of Liver Fat Accumulation in Patients With Nash
Higher Education Policy. 56
2012
Comparison of visceral adipose tissue quantification on water suppressed and nonwater-suppressed MRI at 3.0 Tesla.
Journal of magnetic resonance imaging : JMRI. 35(6):1445-52 [DOI] 10.1002/jmri.23582. [PMID] 22246813.
2012
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 55(5):1389-97 [DOI] 10.1002/hep.25539. [PMID] 22183689.
2012
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
Diabetes care. 35(4):873-8 [DOI] 10.2337/dc11-1849. [PMID] 22374640.
2011
Unmet needs in Hispanic/Latino patients with type 2 diabetes mellitus.
The American journal of medicine. 124(10 Suppl):S2-9 [DOI] 10.1016/j.amjmed.2011.07.017. [PMID] 21939795.
2011
Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo.
Metabolism: clinical and experimental. 60(8):1090-9 [DOI] 10.1016/j.metabol.2010.12.001. [PMID] 21310443.
2011
Insulin sensitizers in nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 53(4):1404-5; author reply 1405 [DOI] 10.1002/hep.24179. [PMID] 21480350.
2011
Focus On Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies Introduction
Endocrine Practice. 17:3-4
2011
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 54(3):837-45 [DOI] 10.1002/hep.24483. [PMID] 21674556.
2011
Comment on: Hoeg et al. Lipid-induced insulin resistance affects women less than men and is not accompanied by inflammation or impaired proximal insulin signaling. Diabetes 2011;60:64-73.
Diabetes. 60(9) [DOI] 10.2337/db11-0687. [PMID] 21868787.
2011
Challenges and opportunities in the management of the Hispanic/Latino patient with type 2 diabetes mellitus. Introduction.
The American journal of medicine. 124(10 Suppl) [DOI] 10.1016/j.amjmed.2011.07.016. [PMID] 21939792.
2011
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
Therapeutic advances in endocrinology and metabolism. 2(5):211-25 [DOI] 10.1177/2042018811419157. [PMID] 23148186.
2011
Focus On the Type 2 Diabetes Patient With Liver Disease: Emphasis On Nonalcoholic Fatty Liver Disease (Nafld)
Endocrine Practice. 17:9-13
2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 10(2):73-84 [DOI] 10.2165/10061630-000000000-00000. [PMID] 20136164.
2010
Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects.
Cardiovascular diabetology. 9 [DOI] 10.1186/1475-2840-9-9. [PMID] 20158910.
2010
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
The Journal of clinical endocrinology and metabolism. 95(2):829-36 [DOI] 10.1210/jc.2009-1487. [PMID] 20061429.
2010
Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.
Clinical endocrinology. 73(3):339-45 [DOI] 10.1111/j.1365-2265.2010.03811.x. [PMID] 20455891.
2010
The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes.
Current diabetes reports. 10(4):306-15 [DOI] 10.1007/s11892-010-0122-6. [PMID] 20556549.
2009
Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.
Clinics in liver disease. 13(4):545-63 [DOI] 10.1016/j.cld.2009.07.009. [PMID] 19818304.
2009
Thiazolidinediones in NASH. An odd couple meant to be?
Journal of clinical gastroenterology. 43(6):503-5 [DOI] 10.1097/MCG.0b013e3181a15e51. [PMID] 19384246.
2009
Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
Current opinion in endocrinology, diabetes, and obesity. 16(2):141-9 [DOI] 10.1097/MED.0b013e3283293015. [PMID] 19262374.
2009
Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 50(4):1087-93 [DOI] 10.1002/hep.23116. [PMID] 19670459.
2009
Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus.
Current diabetes reports. 9(3):200-7 [PMID] 19490821.
View on: PubMed
2009
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
Annals of medicine. 41(4):265-78 [DOI] 10.1080/07853890802552437. [PMID] 19353360.
2008
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Diabetes care. 31(1):121-7 [PMID] 17909084.
View on: PubMed
2008
Allergic skin reaction to insulin detemir: resolution with continued use.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 14(6):796-7 [PMID] 18996804.
View on: PubMed
2008
Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.
Journal of the cardiometabolic syndrome. 3(3):141-6 [DOI] 10.1111/j.1559-4572.2008.00013.x. [PMID] 18983329.
2008
Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise.
American journal of physiology. Endocrinology and metabolism. 294(3):E607-14 [DOI] 10.1152/ajpendo.00729.2007. [PMID] 18182465.
2007
Contrast-enhanced first-pass myocardial perfusion magnetic resonance imaging with parallel acquisition at 3.0 Tesla.
Investigative radiology. 42(6):352-60 [PMID] 17507805.
View on: PubMed
2007
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
American journal of physiology. Endocrinology and metabolism. 292(6):E1775-81 [PMID] 17299078.
View on: PubMed
2007
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
Journal of hepatology. 47(4):565-70 [PMID] 17560678.
View on: PubMed
2007
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
Gastroenterology. 133(2):496-506 [PMID] 17681171.
View on: PubMed
2007
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism. 92(4):1249-55 [PMID] 17244786.
View on: PubMed
2007
The role of fenofibrate in clinical practice.
Diabetes & vascular disease research. 4 Suppl 3:S15-20 [PMID] 17935056.
View on: PubMed
2006
First-pass contrast-enhanced myocardial perfusion MRI using a maximum up-slope parametric map.
IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society. 10(3):574-80 [PMID] 16871727.
View on: PubMed
2006
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Clinical pharmacology and therapeutics. 80(2):105-14 [PMID] 16890572.
View on: PubMed
2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
The New England journal of medicine. 355(22):2297-307 [PMID] 17135584.
View on: PubMed
2006
Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism. 91(12):4903-10 [PMID] 17018657.
View on: PubMed
2005
Dose-response effect of elevated plasma free fatty acid on insulin signaling.
Diabetes. 54(6):1640-8 [PMID] 15919784.
View on: PubMed
2005
Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle.
The Journal of biological chemistry. 280(11):10290-7 [PMID] 15598661.
View on: PubMed
2004
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.
American journal of physiology. Endocrinology and metabolism. 287(3):E537-46 [PMID] 15126243.
View on: PubMed
2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
The Journal of clinical endocrinology and metabolism. 89(9):4649-55 [PMID] 15356076.
View on: PubMed
2003
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
Diabetes. 52(10):2461-74 [PMID] 14514628.
View on: PubMed
2003
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.
Proceedings of the National Academy of Sciences of the United States of America. 100(14):8466-71 [PMID] 12832613.
View on: PubMed
2002
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.
American journal of physiology. Endocrinology and metabolism. 282(6):E1360-8 [PMID] 12006367.
View on: PubMed
2002
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism. 87(6):2784-91 [PMID] 12050251.
View on: PubMed
2002
Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans.
American journal of physiology. Endocrinology and metabolism. 283(2):E346-52 [PMID] 12110541.
View on: PubMed
2002
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.
Diabetes. 51(10):3043-8 [PMID] 12351445.
View on: PubMed
2002
Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes.
Diabetes. 51(2):462-8 [PMID] 11812756.
View on: PubMed
2001
Exercise increases hexokinase II mRNA, but not activity in obesity and type 2 diabetes.
Metabolism: clinical and experimental. 50(5):602-6 [PMID] 11319725.
View on: PubMed
2001
Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis.
American journal of physiology. Endocrinology and metabolism. 280(5):E712-9 [PMID] 11287353.
View on: PubMed
1995
Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle.
The American journal of physiology. 269(4 Pt 1):E701-8 [PMID] 7485484.
View on: PubMed

Grants

Sep 2020 ACTIVE
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2020 ACTIVE
Esterase-Sensitive Hyperpolarized 13C Probes for Simultaneous Imaging of pH and Energy Metabolism
Role: Co-Investigator
Funding: NATL INST OF HLTH NIBIB
May 2020 ACTIVE
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Mar 2019 ACTIVE
Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics
Role: Co-Investigator
Funding: OHIO UNIV via NATL INST OF HLTH NIMHD
Sep 2018 – Aug 2020
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) NOD Study
Role: Principal Investigator
Funding: MD ANDERSON CANCER CENTER via NATL INST OF HLTH NIDDK
Dec 2017 ACTIVE
Miscellaneous Donors Project
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Sep 2016 – Aug 2020
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)
Role: Principal Investigator
Funding: MD ANDERSON CANCER CENTER via NATL INST OF HLTH NIDDK
Jul 2016 ACTIVE
Imaging Hepatic Gluconeogenesis with Hyperpolarized Dihydroxyacetone
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
May 2016 – Sep 2017
Developing a Novel Screening Strategy in Overweight & Obese Children at Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
Role: Other
Funding: ENDOCRINE FELLOWS FOU
Sep 2015 – Dec 2018
Endothelial Dysfunction in Older Adults with Type 2 Diabetes: Effect of Exercise
Role: Project Manager
Funding: NATL INST OF HLTH NIA
Sep 2015 – Aug 2020
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Jan 2015 – Jun 2016
Closing the Care Gap: an Interdisciplinary Approach to Post-fracture Care
Role: Project Manager
Funding: SHANDS TEACHING HOSPITAL HEALTHCARE
Jun 2014 ACTIVE
Obesity and Type-2 Diabetes: Bariatric Surgery Effects on Brain Function
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Mar 2014 – Mar 2017
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects with Type 2 Diabetes Mellitus
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Feb 2014 – Sep 2017
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and the Beta Cell Function in Subjects with Type 2 Diabetes Mellitus
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Jan 2013 – Mar 2016
IPA For Nishanth Sunny
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2012 – Jan 2016
IPA for Diane Biernacki
Role: Principal Investigator
Funding: US DEPT OF VETERANS AFFAIRS

Education

Fellowship – Endocrinology, Diabetes and Metabolism
1992 · Baylor University
Medical Degree
1984 · Universidad de Buenos Aires

Teaching Profile

Courses Taught
2014-2018
MDT7200 Elect Top/Medicine
2016
MDC7200 Medicine Clerkship

Contact Details

Phones:
Business:
(352) 273-8655
Emails:
Business:
kcusi@ufl.edu